52
Participants
Start Date
March 29, 2021
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2030
VX-880
Infused into the hepatic portal vein.
RECRUITING
University of Pittsburgh Medical Center Montefiore, Pittsburgh
RECRUITING
Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
VCU Medical Center, Richmond, Richmond
RECRUITING
UHealth Diabetes Research Institute, Miami
RECRUITING
University of Wisconsin, Madison
COMPLETED
Northwestern Organ Transplant Center, Chicago
RECRUITING
University of Chicago, Chicago
RECRUITING
Baylor Scott and White Research Institute, Dallas
RECRUITING
City of Hope, Duarte
RECRUITING
University of California San Francisco, San Francisco
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
University of Alberta, Edmonton, Edmonton
RECRUITING
McGill University Health Centre, Montreal
RECRUITING
Toronto General Hospital (TGH), Toronto
RECRUITING
Vancouver General Hospital, Vancouver
RECRUITING
CHU Lille, Lille
RECRUITING
Centre de recherche en Biomédecine de Strasbourg, Strasbourg
RECRUITING
Dresden Center for Islet Transplantation, Dresden
RECRUITING
IRCCS Ospedale San Raffaele, Milan
RECRUITING
Leiden University, Leiden
RECRUITING
Oslo University Hospital, Oslo
RECRUITING
King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology, Riyadh
RECRUITING
King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology, Riyadh
RECRUITING
Hopiteaux Universitaires de Geneve, Geneva
RECRUITING
Churchill Hospital, Headington
RECRUITING
Royal Infirmary of Edinburgh, Edinburgh
RECRUITING
Cardiovascular, Metabolic Medicine and Sciences, King's College London, London
RECRUITING
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Vertex Pharmaceuticals Incorporated
INDUSTRY